Untangling Dual-Targeting Therapeutic Mechanism of Epidermal Growth Factor Receptor (EGFR) Based on Reversed Allosteric Communication

• Published in: Pharmaceutics Vol. 13; no. 5; p. 747
• Main Authors: Qiu, Yuran, Yin, Xiaolan, Li, Xinyi, Wang, Yuanhao, Fu, Qiang, Huang, Renhua, Lu, Shaoyong
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 18-05-2021; MDPI
• Subjects: allosteric regulation; allosteric site; Binding sites; Cancer therapies; Clinical trials; Communication; Drug resistance; dual-targeting therapeutics; Epidermal growth factor; epidermal growth factor receptor; Kinases; Ligands; molecular dynamics simulations; Mutation; Proteins; Signal transduction; allosteric site; molecular dynamics simulations; dual-targeting therapeutics; allosteric regulation; epidermal growth factor receptor
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics13050747

Dual-targeting therapeutics by coadministration of allosteric and orthosteric drugs is drawing increased attention as a revolutionary strategy for overcoming the drug-resistance problems. It was further observed that the occupation of orthosteric sites by therapeutics agents has the potential to enhance allosteric ligand binding, which leads to improved potency of allosteric drugs. Epidermal growth factor receptor (EGFR), as one of the most critical anti-cancer targets belonging to the receptor tyrosine kinase family, represents a quintessential example. It was revealed that osimertinib, an ATP-competitive covalent EGFR inhibitor, remarkably enhanced the affinity of a recently developed allosteric inhibitor JBJ-04-125-02 for EGFR
. Here, we utilized extensive large-scale molecular dynamics simulations and the reversed allosteric communication to untangle the detailed molecular underpinning, in which occupation of osimertinib at the orthosteric site altered the overall conformational ensemble of EGFR mutant and reshaped the allosteric site via long-distance signaling. A unique intermediate state resembling the active conformation was identified, which was further stabilized by osimertinib loading. Based on the allosteric communication pathway, we predicted a novel allosteric site positioned around K867, E868, H893, and K960 within the intermediate state. Its correlation with the orthosteric site was validated by both structural and energetic analysis, and its low sequence conservation indicated the potential for selective targeting across the human kinome. Together, these findings not only provided a mechanistic basis for future clinical application of the dual-targeting therapeutics, but also explored an innovative perception of allosteric inhibition of tyrosine kinase signaling.